Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors
L01FE02 Panitumumab
D05350 Panitumumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Panitumumab
D05350 Panitumumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D05350 Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03162 EGFR inhibitor
D05350 Panitumumab
Drug classes [BR:br08332]
Antineoplastic
DG03162 EGFR inhibitor
D05350 Panitumumab
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
EGFR
D05350 Panitumumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05350
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05350
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D05350
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05350
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D05350
